Oncolink Features

Find My Cancer Drug

Tipos de Cancer / Cánceres de la Vía Urinaria / Cáncer Ureteral / Recursos de NCI

Link to OncoLink

NCI CANCERLIT^® Search: Urothelial Tract Cancer - October 2002

Imprima English

National Cancer Institute^®
Ultima Vez Modificado: 1 de octubre del 2002

Prostatic urethral leukoplakia with prostatic abscess.
Laparoscopic and renal sparing approaches to tumours of the ureter and kidney.
Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.
Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for
Primary ureteral mucosa-associated lymphoid tissue (MALT) lymphoma--pathological and radiological findings.
Urethral caruncle in a male: a case report.
A long-term course of a primary urethral/paraurethral adenocarcinoma.
Adenoma of the posterior urethra: 131 case report.

Table of Contents

1
UI - 12201944
AU - Kupeli S; Yilmaz E; Atasoy P; Tulunay O
TI - Prostatic urethral leukoplakia with prostatic abscess.
SO - Scand J Urol Nephrol 2002;36(3):234-5
AD - Department of Urology, School of Medicine, University of Ankara, Turkey.
We present a case of prostatic abscess and coexistent leukoplakia of the urethra in a 51-year-old man. He had been suffering from diabetes mellitus for 10 years and following cessation of high fewer, transurethral electrovaporesection was performed.

2
UI - 12031867
AU - Tolley DA; Esposito MP
TI - Laparoscopic and renal sparing approaches to tumours of the ureter and kidney.
SO - Surg Oncol 2002 Jun;11(1-2):47-54
AD - Scottish Lithotriptor Centre, Western General Hospital, Edinburgh, UK. datollet@baus.org.uk
Until recently, malignancies of the kidney and ureter were managed with open radical surgery. Over the last decade the urologic community has adopted the skill of laparoscopic surgery for the treatment of these tumours. Parenchymal sparing procedures have become the standard of care in the treatment of selected patients with renal and ureteral tumours and many of these surgical procedures can be performed laparoscopically or ureteroscopically. Due partly to necessity and partly to the advancement of technology, renal and ureteral sparing procedures have become commonplace for definitive treatment and palliation of these tumours. The morbidity of such procedures is significantly less than for open surgery and the future of urologic minimally invasive surgery appears secure. This review article is aimed at updating the reader in the most recent advances in these techniques.

3
UI - 12237912
AU - Ricci S; Galli L; Chioni A; Iannopollo M; Antonuzzo A; Francesca F;
TI - Vocaturo V; Selli C; Orlandini C; Conte P Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.
SO - Cancer 2002 Oct 1;95(7):1444-50
AD - Division of Medical Oncology, Department of Oncology, S. Chiara University Hospital, Pisa, Italy. s.ricci@med.unipi.it
BACKGROUND: The objective of this study was to evaluate the efficacy and toxicity of gemcitabine plus epirubicin in previously untreated patients with advanced urothelial carcinoma who were not eligible for cisplatin-based regimens. METHODS: Patients with advanced urothelial carcinoma and at least one of the following characteristics were eligible: impaired renal function (creatinine clearance < 60 mL per minute), an Eastern Cooperative Oncology Group performance status (PS) >or= 2, and age >or= 75 years. The treatment included epirubicin 70 mg/m(2) as an intravenous bolus on Day 1 and gemcitabine 1000 mg/m(2) over 30 minutes on Days 1 and 8 of a 21-day cycle. RESULTS: Thirty-eight patients entered the study, and a total of 152 cycles were administered, with a median of 4 cycles per patient (range, 1-6 cycles per patient). The following Grade 3-4 hematologic toxicities were reported (percent of cycles): neutropenia, 22.4%; anemia, 11.2%; and thrombocytopenia, 6.5%. No cardiac, renal, or hepatic toxicities were observed. Dose intensities of epirubicin and gemcitabine were 19.6 mg/m(2) per week (84%) and 532.2 mg/m(2) per week (80%), respectively. There were 2 complete responses (5.3%), 13 partial responses (34.2%), 11 patients with stable disease (28.9%), and 12 patients with progressive disease (31.6%), for an overall response rate of 39.5% (95% confidence interval, 25.1-55.1). The median progression free survival (PFS) and overall survival (OS) rates were 4.8 months and 8.0 months, respectively. The 1-year survival rate was 38%, and the median PFS and OS were 6.4 months and 16.4 months, respectively, in patients with PS 0-1. Thirty patients were symptomatic: Seventeen patients (56.7%) achieved a complete response, and 5 patients (16.7%) achieved a partial symptomatic response. CONCLUSIONS: At the doses given in this study, gemcitabine and epirubicin had a good tolerability profile with interesting activity in patients with advanced urothelial carcinoma who were not fit for cisplatin-based regimens. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10860

4
UI - 12352398
AU - Thalmann GN; Markwalder R; Walter B; Studer UE
TI - Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
SO - J Urol 2002 Oct;168(4 Pt 1):1381-5
AD - Department of Urology, University of Bern, Switzerland.
PURPOSE: Carcinoma in situ and urothelial tumors of the upper urinary tract become problematic in cases of bilateral occurrence or solitary kidney. Perfusions with bacillus Calmette-Guerin (BCG) have been reported beneficial, however, only long-term results will determine the validity of this treatment. MATERIALS AND METHODS: We retrospectively evaluated the results of BCG therapy for upper urinary tract disease in 37 patients. All 37 patients had undergone previous surgical treatment for urothelial cancer, had a positive cytology or biopsy for upper urinary tract cancer and were ineligible for radical nephroureterectomy with a bladder cuff. After placement of a 10Fr nephrostomy tube with the patient under local anesthesia 6 weekly perfusions of BCG were administered after radiological documentation of unhindered flow from the renal pelvis to the bladder or urinary diversion. A total of 25 renal units were treated with curative intent for carcinoma in situ and 16 renal units were treated for Ta or higher urothelial tumors in an adjuvant setting after endoscopic resection. RESULTS: In 37 patients 41 renal units were treated with BCG perfusions and were followed for a median of 42 months (range 8 to 137). In 1 patient BCG inflammation and in 2 others severe septicemia developed after the first perfusion. There was no tumor seeding along the nephrostomy tract in any patient. BCG perfusion therapy did not alter renal function. Overall median survival was 42 months (range 1 to 137), median recurrence-free survival was 21 months (1 to 137) and progression-free survival was 34 months (1 to 118). Of the 37 patients 14 (38%) died of urothelial cancer, 11 of other causes (29%) and 12 (33%) are alive. CONCLUSIONS: BCG perfusion therapy of the upper urinary tract for papillary tumors or carcinoma in situ is a valid treatment option with acceptable side effects for patients not amenable to conventional radical surgical therapy. BCG therapy of upper urinary tract urothelial tumors may prevent patients from requiring dialysis and provides cure in those with carcinoma in situ of the upper urinary tract. In this negatively selected patient population BCG buys time for some but does not provide cure except for carcinoma in situ.

5
UI - 12002603
AU - Hara M; Satake M; Ogino H; Itoh M; Miyagawa H; Hashimoto Y; Okabe M;
TI - Inagaki H Primary ureteral mucosa-associated lymphoid tissue (MALT) lymphoma--pathological and radiological findings.
SO - Radiat Med 2002 Jan-Feb;20(1):41-4
AD - Department of Radiology, Nagoya City University Medical School, Kawasumi, Japan.
In this report we describe the pathological and radiological findings in a patient with primary ureteral MALT lymphoma. We suggest that it is useful for the differential diagnosis of ureter masses that some MALT lymphomas may show a low signal intensity on T2-weighted MR images.

6
UI - 11952296
AU - Karthikeyan K; Kaviarasan PK; Thappa DM
TI - Urethral caruncle in a male: a case report.
SO - J Eur Acad Dermatol Venereol 2002 Jan;16(1):72-3
AD - Department of Dermatology and STD, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India.
Urethral caruncle in a 60-year-old male labourer is being reported. Its occurrence in male urethra has not been reported so far in the literature.

7
UI - 11147749
AU - Terzic MM; Stimec BV
TI - A long-term course of a primary urethral/paraurethral adenocarcinoma.
SO - Int Urogynecol J Pelvic Floor Dysfunct 2000 Dec;11(6):392-4
AD - Department of Obstetrics and Gynecology, School of Medicine, Belgrade University, Yugoslavia. milanter@EUnet.yu
The authors report a rare case of primary urethral/paraurethral adenocarcinoma in a female patient. The tumor was first detected at the external and internal urethral orifices, with later recurrences in the region of the urinary bladder neck. Histology did not reveal the exact origin of the malignancy. The patient was treated by transurethral resection, regularly repeated during the 3-6-monthly checks. Five years after diagnosis she remains symptom free and has a high quality of life.

8
UI - 11250797
AU - Mi ZG; Yang XF; Liang XZ; Liu HY; Liu SY; Zhang H; Wang DW; Liu C
TI - Adenoma of the posterior urethra: 131 case report.
SO - Asian J Androl 2001 Mar;3(1):67-70
AD - Department of Urology, The First Affiliated Hospital, Shanxi Medical University, Taiyuan, China.
AIM: A case-report on adenoma of the posterior urethra. METHODS: In 131 cases of adenoma of the posterior urethra, aged 17-79 (mean: 36.4) years, a detailed medical history was taken and urinalysis, urethroscopy, and prostatic specific antigen (PSA) immunohistochemical staining were performed. They were then treated with transurethral resection (TUR) or transurethral electric coagulation (TUEC). RESULTS: Hemospermia occurred in 51% of the cases, hematuria in 38%, blood overflow from the urethral orifice in 6%, and dysuria in 5%. The position of the tumor was at or around the verumontanum. The appearance of the tumor was similar to those of a papilla, a villus, a dactyl or polyp, or simply an engorgement. The tumor contained glandular alveoli and adeno-epithelial cells. PSA immunohistochemistry was positive in the cytoplasm and nucleus of the adeno-epithelial cell. One hundred and tweenty-nine cases were cured after TUR or TUEC, while 2 patients recurred and were operated again. CONCLUSION: Adenoma of the posterior urethra is a common cause of hemospermia and hematuria in young men. Urethroscopic examination and biopsy are the principal diagnostic measures. TUR or TUEC are believed to be the treatment of choice with a short-term recurrence rate of around 1. 5%.

The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.

OncoLink I wish u knew...

Ms. Nibauer-Cohen talks about how yoga can help people with cancer cope with the stresses of the diagnosis. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews

Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement